‘Global Urology Devices Market Worth $7,793m In 2020’ Says Visiongain Report

30 August 2018
Pharma

Visiongain’s new report Global Urology Devices Market Forecast to 2026: Urinary Incontinence, Benign Prostatic Hyperplasia (BPH), Kidney Stone, Prostate Cancer indicates that the global Urology Devices market will see $7,793m in spending in 2020.

The global urology devices market is expected to grow at a CAGR of 5.8% from 2020-2026 and CAGR of 6.2% from 2016-2020. The market is expected to grow at a CAGR of 6.0% from 2016 to 2026. The market is estimated at $6,126.4 million in 2016, $7,793.0 million in 2020, and $10,971.3 million in 2026.

The lead analyst of the report said: “The market growth is attributed to a number of factors such as aging population, technological advancements, and increasing awareness programs. Other factors contributing to the growth of the market are preference for minimally invasive procedures and rising incidence of obesity.

The market has certain restraining factors such as high cost of devices and social stigma associated with the disease. Healthcare expenditure and automated urology devices showcase a range of opportunities for this market. Automated solutions and robotic systems have widely helped in treatment of urological abnormalities thus drive the market growth in the forecast period.”
The 200-page report contains 91 tables and 80 charts that add visual analysis in order to explain the developing trends within the Global Urology Devices Market. Visiongain provides revenue forecasts for the period 2016-2026 as well as qualitative analyses for the leading segments of this market: Urinary Incontinence Devices, Benign Prostatic Hyperplasia (BPH) Devices, Kidney Stone Devices and Prostate Cancer Devices.

The 200-page report offers market forecasts and analysis for 10 leading national markets and the rest of the world market. In addition, the report contains a dedicated leading companies’ chapter covering companies leading the field in the urology devices market.

The Global Urology Devices Market Forecast to 2026: Urinary Incontinence, Benign Prostatic Hyperplasia (BPH), Kidney Stone, Prostate Cancer report will be of value to anyone who wants to better understand the Urology Devices market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the Urology Devices industry.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Top 25 Vaccines market set to grow to $41bn by 2024” says new Visiongain report

There is an increasing focus to identify diseases that currently do not have a vaccine.

20 June 2019

Read

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever